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ScalabilityThe integration and analysis of large datasets in translational research has become an increasingly challenging
problem.Wepropose a collaborative approach to integrate establisheddatamanagement platformswith existing
analytical systems toﬁll the hole in the value chain between data collection anddata exploitation. Our proposal in
particular ensures data security and provides support for widely distributed teams of researchers. As a successful
example for such an approach, we describe the implementation of a uniﬁed single platform that combines capa-
bilities of the knowledge management platform tranSMART and the data analysis system Genedata Analyst™.
The combined end-to-end platform helps to quickly ﬁnd, enter, integrate, analyze, extract, and share patient-
and drug-related data in the context of translational R&D projects.
© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
A typical challenge that translational researchers in clinical settings,
pharmaceutical R&D and academic centers face is the integration and
analysis of clinical patient data with high-dimensional omics data,
resulting from the examination of individual patient samples. Re-
searchers need to analyze those integrated datasets in order to more ef-
ﬁciently develop new, safer, and more effective drugs. Pharmaceutical
companies have therefore begun developing datamanagement systems
such as the open source platform tranSMART, a knowledge manage-
ment system to store and share patient data (see also the article by
TranSMART Foundation in next issue). tranSMART enables an integrat-
ed way for scientists to store and share curated phenotypic data such as
clinical observations and severe adverse events (SAEs), biomarker data
from gene expression, genotyping, unstructured text from sources such
as journal articles and conference abstracts, reference data, andmetada-
ta (Athey et al., 2013). However, tranSMART is not an end-to-end solu-
tion for the analyses of such data, as it lacks, for example, the ability to
perform cross-study analyses or other more sophisticated statistical
analyses. Although tranSMART provides a limited set of analytical fea-
tures for stratiﬁcation of clinical data into molecular subtypes, Target
Enrichment Analysis, and summary statistics, among others, it does
not provide enough analytical capabilities to generate answers to typi-
cal questions in biomarker identiﬁcation and validation and sample
classiﬁcation and prediction. Generally speaking, highly scalableberry Hill, Suite 403; Lexington,
ens).
en access article under the CC BY-NCenterprise solutions that ﬁll the analytics gap in the translational value
chain and that integrate platforms such as tranSMART were, until re-
cently, still missing. One reason is that computational analysis and bio-
logical interpretation of high-dimensional omics data (i.e. genomics,
transcriptomics, epigenomics, proteomics, andmetabolomics) pose sig-
niﬁcant challenges. For example, 1) the statistical and visual interpreta-
tion of data derived from different technological platforms is
exceptionally complex, in part due to the large number of parameters;
and 2), to fully exploit and compare data from different studies and/or
technologies, analytical platforms need intelligent systems that can in-
teract with the tranSMART data warehouse bidirectionally, without
the need of exporting data to different ﬁle formats during the process.
In a collaborative effort, with partners from the pharmaceutical
tranSMART user community, we tackled those issues to ﬁll the gaps in
the translational value chain by integrating tranSMART with Genedata
Analyst™, a multi-omics data analysis platform. It is capable not only
to easily import integrated data from tranSMART for in-depth statistical
analyses, but also to provide a bidirectional, interactive data-ﬂow back
to the tranSMART system, with the option to integrate additional
data from other public repositories, such as COSMIC, dbGaP, GEO,
ArrayExpress, TCGA, or dbSNP.
2. Results & discussion
Translational research relies on an integrated set of data, so that dif-
ferent questions can be postulated. tranSMART stores such integrated
data sets from a variety of different established databases, targeting
early stages in the R&D value chain such as clinical data collection.
One example is OpenClinica (Franklin et al., 2011), an open source-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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data management. OpenClinica works primarily in the context of low-
dimensional (clinical) sample information, and includes tools to aid in
protocol design, creation and management of electronic Case Report
Forms (eCRFs), monitoring of studies, and obtain real-time transparen-
cy across multiple studies and sites. Similarly, it is planned to connect
tranSMART to REDCap (Research Electronic Data Capture), a secure
web application for building and managing online research surveys
and databases (Harris et al., 2009). Such open source tools promise to
be a powerful combination: for example, data collected in OpenClinica
can be further shared in the tranSMART environment.
Our focus is combining tranSMART's data warehouse capabilities
with the advanced analytical tools found in Genedata Analyst to provide
inter-disciplinary teams with an integrated research collaboration and
data analysis platform that covers the translational research value
chain, from the patient to drug development (Fig. 1).
To fully utilize the strengths of tranSMART, several functionalities
are required that can be complemented by the strong algorithmic capa-
bilities included in Genedata Analyst. In general, to be useful for transla-
tional research, any analytical platform has to meet the following
requirements:
A. Scalability: Big data processing today is still inefﬁcient inmany areas,
particularly due to 1) the diversity of data formats, use of unstruc-
tured data, and the speed with which it needs to be generated andFig. 1. Example of a data-sharing and big-data analytics value chain in translational medicine.
abundant Omic data adds new dimensions and challenges for the management, analysis, and
OpenClinica or REDCap) may feed patient data into tranSMART for data integration. An in-dep
for the integrated analysis of high-dimensional omics data in the context of low-dimensional (c
tists to efﬁciently analyze experiments by applying rigorous statistical algorithms combined wi
alyst standardizes and automates complex and time-consuming data analysis processes. Via aﬂe
to use popular open source tools such as the R/Bioconductor-environment for downstream an
import, export, integrate, and analyze complex data—from days to minutes. (ETL = Extract, T
been integrated into tranSMART and are freely available to the research community. The statisprocessed. Also, 2) the sheer volume of data is a bottleneck as the
amount of public and proprietary data is exponentially expanding;
in ﬁelds such as genomics, the data collected by new instruments
is outpacing Moore's Law by several orders (O'Driscoll et al., 2013).
Due to their high-dimensional structure,multi-omics approaches in-
herently increase the already surging amount of big data in the life-
sciences. As a consequence, analytical tools must be able to utilize
unstructured data and must provide nearly unlimited scalability to
enable interactive analyses of large data sets with billions of data
points.
B. Open system/ﬂexible plugin APIs: The goal of any analytical platform
is to be system agnostic and able to integrate into an existing IT en-
vironment. As such, ﬂexible plugin APIs are a core requirement, en-
abling the platform to be extensible and to provide users with a
scalable data mining platform capable of easily integrating with in-
house and third party data analysis tools and databases. Public APIs
for data import, export, and statistical analysis give users the free-
dom to automate their own analyses and workﬂows.
C. Access to public data repositories: Integration of public data reposi-
tories with downstream analytical tools able to access to a wide va-
riety of multi-omics data (preferentially with standardized use of
ontology-derived nomenclatures) enables efﬁcient data discovery
and data sharing. Preferentially, the chosen platform should already
contain an out-of-the-box integration with public omics data
sources including GEO, ArrayExpress, and other resources.The collection of large volumes of structured phenotypic data and its integration with the
visualization of this information. Clinical electronic data capture systems (EDCs, such as
th analysis of the data can then be performed in Genedata Analyst, an established system
linical) sample information, often used in translational research projects. It enables scien-
th intuitive, interactive data visualization tools. Leveraging a built-in scripting engine, An-
xible application program interface (API), the analyst platformalso provides thepossibility
alyses (Gentleman et al., 2004). Overall, the platform has the ability to reduce the time to
ransform, and Load process for loading raw source data into tranSMART.) The APIs have
tical analysis software itself is a commercial software available for licensing.
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most importance to ensure the reliability, quality, integrity, and
traceability of electronic source data. Traceability facilitates trans-
parency, which is an essential component in building conﬁdence in
a result. The tranSMART/Analyst interface provides such an architec-
ture for end-to-end traceability of data. The system maintains a
chain of custody and log functionality for all data gathered through-
out the transfer and analysis of the data. This ensures that, at the
point of publication or submission to a regulatory authority, a single
reliable source of data is available to support the ﬁndings. In
addition, measures should be taken to ensure privacy by protecting
patient data and conﬁdentiality. In particular, this could be achieved
by establishing a Health Insurance Portability and Accountability
Act—(HIPPA) compliant environment, ensuring the procedural and
technical measures required to prevent unauthorized access, modi-
ﬁcation, use, and dissemination of data stored or processed in the
platform.
E. Standardization/workﬂows: The platform should allow creation, ex-
ecution, andmanagement ofworkﬂows that can automate and stan-
dardize analyses by providing means to record the processing order
and parameter settings for sets of different analysis activities. This
makes it possible to run analyses fully automated, meaning thatFig. 2. Example of a bidirectional data explorationworkﬂow using the tranSMART/analyst platfo
tured) data by combining and comparing it with structured data sets (where inclusion in a rel
engine algorithms). Left: The advanced workﬂow tab in the tranSMART dataset explorer cont
Analyst through an easy drag and drop concept. 1: The patient cohorts to be examined are sel
(e.g. microarray or NGS data) are selected and transferred by a single mouse-click into the An
quality control steps. 4: Filtered data are selected for in-depth analyses such as PCA, correlation
analyses, pathway mapping, and partial least square analysis (PLS). Third-party tools such as R-
tranSMART via a menu-button. At any point, it is possible to simply pull more clinical/annotatio
vice versa. 6: Analyzed and curated data is available for further storage, sharing, and analyses ieven new users can start using sophisticated analyses by running a
workﬂow inwhich all analysis steps are incorporated (i.e. assembled
by a more experienced user).
F. Vendor support/technology agnosticism: Any system should be able
to support a wide variety of omics-technologies (e.g. different next
generation sequencing or mass spectrometry platforms) and easily
integrate data from all available vendors.
G. Bi-directional data-ﬂow: It should be easily possible to upload con-
tent that went through technology speciﬁc preprocessing and qual-
ity control steps in the analytical platformback into tranSMART via a
secure system to system communication. Such data could, for exam-
ple, consist of transformed or normalized data, e.g. from next gener-
ation sequencing (NGS)-, qPCR, microarray or mass spectrometry
technologies. Such technologies are revolutionizing translational re-
search by producing massive quantities of data that are being made
publically available or shared within an enterprise. However, data
that will be used by a wide variety of researchers need to be of espe-
cially high quality. As such, traditional approaches to preprocessing
and quality control are no longer practical when confronted with
the size of these data sets and the demands of real-time processing.
Automated workﬂows for rapidly identifying problematic data are
essential. Use of automated tools would enhance data integrity andrm. The platform is designed to improve understanding of large amounts of raw (unstruc-
ational database is seamless and it is readily searchable by simple, straightforward search
ains a button (red rectangle) that makes clinical data available for statistical analyses in
ected and further inclusion criteria can be deﬁned. 2: Multi-omics, high dimensional data
alyst GUI. 3: For curation purposes, imported data can be run through preprocessing and
, network analyses, logistic regression, ANOVA, time-series analysis, clustering, annotation
scripts can also be integrated. 5: The results of the analysis can be saved directly back into
n data from tranSMART (and other sources such as GEO or ArrayExpress) into Analyst and
n tranSMART.
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still conﬁdence in the shared omics data, thereby improving interop-
erability across research networks.
H. Ease-of use: An often neglected point in translational research is the
ease-of-use of bioinformatics solutions. When researchers are faced
with clinical data analysis tools, it is often found that the importance
of ease-of-use and training materials outweighs number of features
and functionality (Gomez-Cabrero et al., 2014). The whole integra-
tion process should contain an intuitive interface with pre-
packaged features and easy accessible workﬂows making it easy to
use for all user levels. Optimally, this bidirectional data-transfer
can be performed with a single click of a button (see Fig. 2).
Due to the active interaction with the tranSMART community, all of
the above listed criteria were fulﬁlled and combined into a single robust
platform. The tranSMART/Analyst platform integrates and analyzes ge-
nomic, transcriptomic, epigenetic, and phenotypic data within a single
high-throughput systemandprocesses large and complex experimental
data sets from all major vendors and technology platforms. tranSMART
is a fully translational data warehouse based on the open-source i2b2
platform (Informatics for Integrating Biology and the Bedside; http://
www.i2b2.org) that offers the functionality to integrate patient out-
comes and electronic medical records (EMRs) to help effectively mine
data. Analyst has an integrationwith additional studymanagement sys-
tems and ontologies, which ensures that the processed data conforms to
established standards and the user can be sure to publish only curated
data back into the tranSMART system, in a fast and highly scalable fash-
ion, without the necessity to export the data to a different format ﬁrst.
Furthermore, additional collaborative improvements of the platform
and integration of other translational/clinical platforms such as iRODS
are planned and encouraged.
3. Conclusions
We propose a collaborative approach to tackle the data integration
and analytics challenge found within translational research. We have
demonstrated that this approach could lead to a powerful platform by
implementing a technical integration of tranSMART with Genedata An-
alyst. The tranSMART/Analyst platform provides a uniﬁed solution that
integrates big data analytics capabilitieswith translational research data
management and empowers scientists to efﬁciently analyze high-dimensional omics data based on subsets of clinical variables. This
setup signiﬁcantly reduces time and cost for data analysis and helps to
understand the complexity and dynamics of biological processes with-
out the need to reduce this complexity to artiﬁcial levels that may be
less meaningful. Overall, the tranSMART/Analyst platform supports a
richer analysis of bio-molecular proﬁling data, enables efﬁcient cross-
study data analysis, and integrates technology-speciﬁc data preprocess-
ing and quality control capabilities. Those features eliminate error-
prone manual data handling and data transformation processes and
foster collaboration among global research teams by providing stan-
dardized analysis workﬂows. Ultimately, such a platform supports the
scientiﬁc community's need to share data, collaborate to improve diag-
nostics, and to discover more effective treatments for patients suffering
from complex diseases.
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